Healthcare entity
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Eli Lilly, the most common co-covered peer. They are better corroborated than the beat average, carrying 6 original sources each against 3 for the same window.
Last mentioned: Mar 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Eli Lilly, the most common co-covered peer. They are better corroborated than the beat average, carrying 6 original sources each against 3 for the same window. The 7 average consequence score is above the beat benchmark of 5.9 in the same window. We currently track 1 Healthcare story that mention GLP-1 Agonists, all published on March 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering GLP-1 Agonists. Shared-story counts are live from our verified record — not editorial picks.
Pitt Breakthrough
Researchers reveal a new approach to bypass leptin resistance at the molecular level.
GLP-1 Dominance
Drugs like Wegovy and Zepbound revolutionize the obesity market.
Clinical Failures
Early leptin trials fail due to the discovery of leptin resistance in obesity.
Discovery of Leptin
Jeffrey Friedman identifies the hormone as a key regulator of body weight.
University of Pittsburgh researchers have identified a new mechanism to overcome leptin resistance, a major hurdle in obesity treatment. This approach aims to restore the brain's sensitivity to satiety signals, potentially offering a sustainable alternative to current GLP-1 therapies.
GLP-1 Agonists is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
